Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Urogen Pharma Ltd (NQ: URGN ) 16.55 -0.32 (-1.90%) Streaming Delayed Price Updated: 10:00 AM EDT, Jun 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 54,025 Open 16.80 Bid (Size) 16.55 (9) Ask (Size) 16.59 (2) Prev. Close 16.87 Today's Range 16.50 - 16.85 52wk Range 8.690 - 24.13 Shares Outstanding 36,130,121 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session June 18, 2024 Via Benzinga UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants June 17, 2024 From UroGen Pharma Ltd. Via Business Wire Performance YTD +8.81% +8.81% 1 Month +28.20% +28.20% 3 Month +10.63% +10.63% 6 Month +11.30% +11.30% 1 Year +41.57% +41.57% More News Read More Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday June 14, 2024 Via Benzinga Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday June 14, 2024 Via Benzinga UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug June 13, 2024 Via Investor's Business Daily UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC June 13, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Host UGN-102 Virtual Data Event on June 13, 2024 June 06, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference June 05, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma Appoints David Lin as New Chief Commercial Officer June 03, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit May 22, 2024 From UroGen Pharma Ltd. Via Business Wire URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 May 13, 2024 Via InvestorPlace UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights May 13, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Participate at Upcoming Investor Conferences May 07, 2024 From UroGen Pharma Ltd. Via Business Wire New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy May 05, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 May 04, 2024 From UroGen Pharma Ltd. Via Business Wire New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial May 04, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 May 03, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers April 17, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer April 15, 2024 From UroGen Pharma Ltd. Via Business Wire UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals April 03, 2024 From UroGen Pharma Ltd. Via Business Wire Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 25, 2024 Via Benzinga URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 March 14, 2024 Via InvestorPlace UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 March 14, 2024 From UroGen Pharma Ltd. Via Business Wire Earnings Scheduled For March 14, 2024 March 14, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
